BEAM Alliance

Driving Innovation, Shaping Policy:
Europe’s SMEs United Against AMR

BEAM at work

Our advocacy work is based on analysis and reflection with our members.
Each topic is dealt with by a task force, which acts as a discussion platform and issues policy briefs.

PULL incentives
PUSH incentives
Diagnostics
Prevention

Evaluation
Phages
National actions
BEAM papers

Members

Latest news

24 February 2026

Centauri Therapeutics extends Series A to £30M with £6M investment from AMR Action Fund to support progression of lead clinical candidate

The funding from AMR Action Fund, the world’s largest venture capital fund dedicated exclusively to investing in urgently needed antimicrobial…

19 February 2026

BioVersys and partners’ phase 2a tuberculosis trial results published in New England Journal of Medicine

The bEto-TB trial demonstrates the power of sustained investment in global health research. The development of AlpE reflects not only…

9 February 2026

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

We are pleased with the strong sales performance from our partner Pfizer for the Asia Pacific region, including China. This…

All the news

Legal notice | Photo credits

Who we are
Overview
Members
Pipeline
News

Connect with us

contact@beam-alliance.eu
29 Avenue Tony Garnier 69007 Lyon - France